| Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial (NCT00540059) | AstraZeneca | 2005-06-01 |
| Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients (NCT00254787) | AstraZeneca | 2005-06-01 |
| A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer (NCT00544986) | AstraZeneca | 2005-06-01 |
| Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer (NCT00638391) | AstraZeneca | 2005-05-01 |
| Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg (NCT00242775) | AstraZeneca | 2005-05-01 |
| Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08) (NCT00246935) | AstraZeneca | 2005-05-01 |
| Seroquel in Bipolar Depression Versus SSRI (NCT00119652) | AstraZeneca | 2005-05-01 |
| A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler® (NCT00244608) | AstraZeneca | 2005-05-01 |
| AZD1152 in Patients With Advanced Solid Malignancies-Study 1 (NCT00497731) | AstraZeneca | 2005-05-01 |
| A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects (NCT00112021) | AstraZeneca | 2005-05-01 |
| GALLANT 22 Tesaglitazar vs. Placebo (NCT00252837) | AstraZeneca | 2005-04-01 |
| A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD (NCT00206167) | AstraZeneca | 2005-04-01 |
| A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects (NCT00162305) | AstraZeneca | 2005-04-01 |
| A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients (NCT00206154) | AstraZeneca | 2005-04-01 |
| HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease (NCT00243724) | AstraZeneca | 2005-04-01 |
| PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure (NCT00099580) | AstraZeneca | 2005-03-01 |
| GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate (NCT00261352) | AstraZeneca | 2005-03-01 |
| Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo (NCT00228462) | AstraZeneca | 2005-03-01 |
| Quetiapine Fumarate Bipolar Maintenance Monotherapy (NCT00314184) | AstraZeneca | 2005-03-01 |
| GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes (NCT00252876) | AstraZeneca | 2005-03-01 |
| GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus (NCT00226330) | AstraZeneca | 2005-03-01 |
| Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. (NCT00099437) | AstraZeneca | 2005-02-13 |
| Type III Dysbetalipoproteinemia (NCT00214604) | AstraZeneca | 2005-02-01 |
| GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes (NCT00229710) | AstraZeneca | 2005-02-01 |
| Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) (NCT00659503) | AstraZeneca | 2005-02-01 |
| Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes (NCT00103935) | AstraZeneca | 2005-02-01 |
| Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (NCT00163293) | AstraZeneca | 2005-01-01 |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors (NCT00502567) | AstraZeneca | 2005-01-01 |
| Iressa Follow-up Trial (NCT00357734) | AstraZeneca | 2005-01-01 |
| A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes (NCT00517283) | AstraZeneca | 2005-01-01 |
| Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) (NCT00163488) | AstraZeneca | 2005-01-01 |
| SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma (NCT00290264) | AstraZeneca | 2004-12-01 |
| Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07). (NCT00246922) | AstraZeneca | 2004-12-01 |
| Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder (NCT00306540) | AstraZeneca | 2004-12-01 |
| A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma (NCT01365533) | AstraZeneca | 2004-12-01 |
| DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults (NCT00252863) | AstraZeneca | 2004-12-01 |
| Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408) (NCT00659048) | AstraZeneca | 2004-12-01 |
| Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] (NCT00094328) | AstraZeneca | 2004-11-22 |
| Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) (NCT00659594) | AstraZeneca | 2004-11-01 |
| Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age (NCT00244621) | AstraZeneca | 2004-11-01 |
| Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142) (NCT00163423) | AstraZeneca | 2004-11-01 |
| IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma (NCT00229723) | AstraZeneca | 2004-11-01 |
| Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101) (NCT00163319) | AstraZeneca | 2004-11-01 |
| Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06) (NCT00242294) | AstraZeneca | 2004-11-01 |
| SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia (NCT00206115) | AstraZeneca | 2004-11-01 |
| Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia (NCT00206128) | AstraZeneca | 2004-11-01 |
| Acid-Associated Heartburn Symptoms and Dose of Esomeprazole (NCT00206024) | AstraZeneca | 2004-11-01 |
| Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia (NCT00234377) | AstraZeneca | 2004-11-01 |
| An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication (NCT00577265) | AstraZeneca | 2004-11-01 |
| Phase II Iressa & Carbo/Gem in NSCLC (NCT00264498) | AstraZeneca | 2004-10-01 |
| Fast Titration Of Quetiapine Versus Currently Approved Titration (NCT00254813) | AstraZeneca | 2004-10-01 |
| Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206) (NCT00163462) | AstraZeneca | 2004-10-01 |
| Esomeprazole for Treatment of GERD in Pediatric Patients (NCT00228527) | AstraZeneca | 2004-10-01 |
| Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer (NCT00239343) | AstraZeneca | 2004-10-01 |
| SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma (NCT00288379) | AstraZeneca | 2004-10-01 |
| The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121) (NCT00108823) | AstraZeneca | 2004-10-01 |
| Iressa v BSC (Best Supportive Care) in First Line NSCLC (NCT00259064) | AstraZeneca | 2004-09-01 |
| Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy (NCT00099619) | AstraZeneca | 2004-09-01 |
| Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po (NCT00206050) | AstraZeneca | 2004-09-01 |
| Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes (NCT00097500) | AstraZeneca | 2004-09-01 |
| GALLANT 4 Tesaglitazar vs. Glibenclamide (NCT00255541) | AstraZeneca | 2004-09-01 |
| SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults (NCT00259792) | AstraZeneca | 2004-09-01 |
| ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) (NCT00229684) | AstraZeneca | 2004-09-01 |
| A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women (NCT00228475) | AstraZeneca | 2004-09-01 |
| A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents (NCT01077323) | AstraZeneca | 2004-09-01 |
| To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) (NCT00658918) | AstraZeneca | 2004-09-01 |
| Phase II Iressa + Irradiation Followed by Chemo in NSCLC (NCT00333294) | AstraZeneca | 2004-09-01 |
| MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults (NCT00242411) | AstraZeneca | 2004-09-01 |
| Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal (NCT00240344) | AstraZeneca | 2004-09-01 |
| Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia (NCT00090324) | AstraZeneca | 2004-09-01 |
| GALLANT 2 Tesaglitazar vs. Placebo (NCT00252772) | AstraZeneca | 2004-09-01 |
| A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer (NCT00298688) | AstraZeneca | 2004-09-01 |
| GALLANT 5 Tesaglitazar Versus Metformin (NCT00214591) | AstraZeneca | 2004-08-01 |
| Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects (NCT00444561) | AstraZeneca | 2004-08-01 |
| Fast Titration in the Treatment of Schizophrenia, Taiwan (NCT00304473) | AstraZeneca | 2004-08-01 |
| Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (NCT00227305) | AstraZeneca | 2004-08-01 |
| GALLANT 6 Tesaglitazar vs. Pioglitazone (NCT00214565) | AstraZeneca | 2004-08-01 |
| Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (NCT00075959) | AstraZeneca | 2004-08-01 |
| CMAB vs IMAB in Metastatic Prostate Cancer (NCT00255268) | AstraZeneca | 2004-08-01 |
| GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin (NCT00242372) | AstraZeneca | 2004-08-01 |
| Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer (NCT00502060) | AstraZeneca | 2004-08-01 |
| Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer (NCT00234442) | AstraZeneca | 2004-07-01 |
| Arimidex Observational: Reason for and Effect of Change From Tamoxifen (NCT00246961) | AstraZeneca | 2004-07-01 |
| GALLANT 8 Tesaglitazar Add-on to Metformin (NCT00251953) | AstraZeneca | 2004-07-01 |
| Phase II Iressa Versus Vinorelbine (INVITE) (NCT00256711) | AstraZeneca | 2004-07-01 |
| ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) (NCT00090363) | AstraZeneca | 2004-07-01 |
| Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania (NCT00090311) | AstraZeneca | 2004-07-01 |
| ZAP, US. Zomig for Appropriate for Primary Care (NCT00637286) | AstraZeneca | 2004-07-01 |
| AZD5438 in Patients With Advanced Solid Malignancies (NCT00088790) | AstraZeneca | 2004-07-01 |
| Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer (NCT00233623) | AstraZeneca | 2004-07-01 |
| GALLANT 7 Tesaglitazar Add-on to Sulphonylurea (NCT00251940) | AstraZeneca | 2004-07-01 |
| Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients (NCT00254748) | AstraZeneca | 2004-06-01 |
| Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg (NCT00653445) | AstraZeneca | 2004-06-01 |
| NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis (NCT00206180) | AstraZeneca | 2004-06-01 |
| The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients (NCT00524251) | AstraZeneca | 2004-06-01 |
| A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients (NCT00625274) | AstraZeneca | 2004-06-01 |
| Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia (NCT00085891) | AstraZeneca | 2004-06-01 |
| Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole (NCT00623519) | AstraZeneca | 2004-06-01 |
| Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (NCT00093002) | AstraZeneca | 2004-06-01 |
| Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression (NCT00083954) | AstraZeneca | 2004-06-01 |